Literature DB >> 31538643

Oseltamivir Resistance in Severe Influenza A(H1N1)pdm09 Pneumonia and Acute Respiratory Distress Syndrome: A French Multicenter Observational Cohort Study.

Sylvie Behillil1, Faten May2,3, Slim Fourati4, Charles-Edouard Luyt5, Thomas Chicheportiche5, Romain Sonneville6, Yacine Tandjaoui-Lambiotte7, Damien Roux8, Laurent Guérin9, Julien Mayaux10, Eric Maury11, Alexis Ferré12, Jean-François Georger13, Guillaume Voiriot14, Vincent Enouf1, Sylvie van der Werf1, Armand Mekontso Dessap2,3, Nicolas de Prost2,3.   

Abstract

In a multicenter cohort study including 22 oseltamivir-treated patients with influenza A(H1N1)pdm09 acute respiratory distress syndrome, prevalence of the H275Y substitution in the neuraminidase, responsible for highly reduced sensitivity to oseltamivir, was 23%. Patients infected with the H275Y mutant virus had higher day 28 mortality than others (80% vs 12%; P = .011).
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  H1N1 subtype; adult; influenza A virus; oseltamivir; pneumonia; respiratory distress syndrome; viral

Year:  2020        PMID： 31538643     DOI： 10.1093/cid/ciz904

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  7 in total

1.  Characterization of influenza A(H1N1)pdm09 isolates of Peru using HRM, a post PCR molecular biology method.

Authors:  Priscila Lope; Huaringa Maribel; Mayta Egma; Bailon Henri; Padilla Carlos
Journal:  Bioinformation       Date:  2019-10-10

2.  Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza.

Authors:  Yeming Wang; Wu Zhong; Alex Salam; Joel Tarning; Qingyuan Zhan; Jian-An Huang; Heng Weng; Changqing Bai; Yanhong Ren; Koichi Yamada; Dayan Wang; Qiang Guo; Qiongqiong Fang; Sakurai Tsutomu; Xiaohui Zou; Haibo Li; Annelies Gillesen; Lyndsey Castle; Cheng Chen; Hongyan Li; Jing Zhen; Binghuai Lu; Jun Duan; Liping Guo; Jinfang Jiang; Ruiyuan Cao; Guohui Fan; Jintong Li; Frederick G Hayden; Chen Wang; Peter Horby; Bin Cao
Journal:  EBioMedicine       Date:  2020-11-22       Impact factor: 8.143

Review 3.  Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.

Authors:  Michael G Ison; Frederick G Hayden; Alan J Hay; Larisa V Gubareva; Elena A Govorkova; Emi Takashita; Jennifer L McKimm-Breschkin
Journal:  Antiviral Res       Date:  2021-08-04       Impact factor: 10.103

4.  Investigation of Human IFITM3 Polymorphisms rs34481144A and rs12252C and Risk for Influenza A(H1N1)pdm09 Severity in a Brazilian Cohort.

Authors:  Jéssica S C Martins; Maria L A Oliveira; Cristiana C Garcia; Marilda M Siqueira; Aline R Matos
Journal:  Front Cell Infect Microbiol       Date:  2020-07-10       Impact factor: 5.293

Review 5.  Critical care management of adults with community-acquired severe respiratory viral infection.

Authors:  Yaseen M Arabi; Robert Fowler; Frederick G Hayden
Journal:  Intensive Care Med       Date:  2020-02-10       Impact factor: 17.440

6.  Overcome Double Trouble: Baloxavir Marboxil Suppresses Influenza Thereby Mitigating Secondary Invasive Pulmonary Aspergillosis.

Authors:  Laura Seldeslachts; Cato Jacobs; Birger Tielemans; Eliane Vanhoffelen; Lauren Van der Sloten; Stephanie Humblet-Baron; Lieve Naesens; Katrien Lagrou; Erik Verbeken; Joost Wauters; Greetje Vande Velde
Journal:  J Fungi (Basel)       Date:  2021-12-21

Review 7.  A global treatments for coronaviruses including COVID-19.

Authors:  Bahman Yousefi; Saeid Valizadeh; Hadi Ghaffari; Azadeh Vahedi; Mohsen Karbalaei; Majid Eslami
Journal:  J Cell Physiol       Date:  2020-05-11       Impact factor: 6.513
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.